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Avian Mycoplasma 
lipofaciens 
Transmission to 
Veterinarian
To the Editor: Mycoplasma spp. 
are well-known pathogens in human 
and veterinary medicine. Mammals, 
especially primates and including hu-
mans, share similar or even identical 
Mycoplasma spp., which might be 
commensal or pathogenic (1). Ad-
ditionally, sporadic infections of im-
munocompromised persons with My-
coplasma spp. that originated from 
domestic animals have been reported 
(1); susceptibility in this human popu-
lation is increased (2,3). M. phocicere-
brale is the only Mycoplasma patho-
gen of animals that regularly infects 
humans, causing a disease called seal 
ﬁ  ngers  (1,4). However, we report a 
human infection with an avian Myco-
plasma organism.
A clinical trial to investigate the 
capability of M. lipofaciens (strain 
ML64) (5) to spread horizontally be-
tween infected and noninfected turkey 
poults in an incubator demonstrated 
airborne transmission of the patho-
gen within 24 hours (6). During the 
trial, the veterinarian conducting the 
study, a 36-year-old man, was moni-
tored for infection. Each day, 2 swabs 
were taken from both nostrils, starting 
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from the day before the infected poults 
hatched (day 0) through day 7 after the 
poult hatching date. When handling 
eggs and poults, the veterinarian wore 
gloves but not a protective mask. Two 
days after the poults hatched (day 3), 
the veterinarian reported throat pain 
and a slight rhinitis, which indicated a 
respiratory disease. The next day only 
the rhinitis with minor nasal pain was 
present.
One nasal swab from each sam-
pling day was used for Mycoplasma 
spp. culture (5). Isolated Mycoplasma 
organisms were subjected to an im-
munobinding assay (6) with antiserum 
against  M. lipofaciens,  M. buteonis, 
M. falconis, M. gypis, M. gallisepti-
cum,  M. meleagridis,  M. synoviae, 
and  M. iowae, selected because the 
veterinarian regularly handled these 
isolates. The second nasal swab from 
each sampling day was taken to detect 
Mycoplasma DNA by PCR (5). The 
samples for PCR testing were stored at 
–20°C and tested only when attempts 
to isolate Mycoplasma spp. failed.
Six weeks after the infection, a 
serum sample from the patient was ex-
amined for speciﬁ  c antibodies against 
M. lipofaciens by 3 different meth-
ods: modiﬁ   ed immunobinding assay 
(6) (which used patient’s serum and 
peroxidase-conjugated goat-antihu-
man serum [STAR90P, Serotec Ltd, 
Oxford, UK]), a growth inhibition 
test, and antibody titers of serum dilu-
tions. The ﬁ  rst 2 methods used M. li-
pofaciens (strain ML64) from a turkey 
trial (6) and the reference strains of M. 
buteonis (Bb/T2g) and M. falconis (H/
T1). For the third method, to deter-
mine the titer, 2-fold serial dilutions 
of the patient’s serum samples were 
prepared and incubated with a bacte-
rial suspension (M. lipofaciens strain 
ML64) containing 3.2 × 102 CFU. The 
antibody titer was based on the high-
est serum dilution capable of reducing 
50% of the mean CFU count.
Before the infected poults hatched, 
attempts to isolate Mycoplasma organ-
isms and demonstrate Mycoplasma 
DNA from the nasal swabs were un-
successful. However, from the day of 
hatching (day 1) until 3 days later (day 
4), Mycoplasma organisms were iso-
lated from the nasal swabs and identi-
ﬁ  ed as M. lipofaciens. On day 5, only 
Mycoplasma DNA was demonstrated 
(Table). Speciﬁ  c antibodies against M. 
lipofaciens (strain ML64) were detect-
ed by using the immunobinding assay 
and growth inhibition test. Antibodies 
against other Mycoplasma spp. were 
not detected. Antibody titer against M. 
lipofaciens was 128.
M. lipofaciens have been reported 
from a chicken, turkey, duck (7,8), 
and a raptor egg (5). Strain ML64 is 
highly pathogenic for chicken and tur-
key embryos and can be transmitted 
by air (6,9). The veterinarian handling 
the infected poults was free of nasal 
Mycoplasma organisms a day before 
contact. His infection occurred con-
current with demonstration of airborne 
transmission among poults. The isola-
tion of M. lipofaciens from his nares 
for 4 days demonstrates the infectiv-
ity and reproductive capability of this 
Mycoplasma strain in humans: as a 
pure contaminant, isolation for several 
days would be unlikely. Christensen et 
al. (10) have reisolated different avian 
Mycoplasma strains (M. gallisepticum, 
M. synoviae, M. iowae) from a human 
nose, from 12 hours through 1 day af-
ter artiﬁ  cial infection, demonstrating 
differences between avian strain abili-
ties to survive on human mucosa. M. 
lipofaciens invasiveness for humans is 
underscored by ﬁ  nding speciﬁ  c anti-
bodies against this species 6 weeks af-
ter infection. Cross-reactivity to other 
Mycoplasma spp. cannot be excluded 
but seems unlikely. 
This study suggests that M. lipofa-
ciens (strain ML64) can be transmitted 
successfully to humans and may cause 
clinical symptoms; the study docu-
ments nonartiﬁ   cial human infection 
with an avian Mycoplasma sp. These 
ﬁ   ndings should be considered espe-
cially for humans highly susceptible 
to  Mycoplasma infections, including 
children and persons with congenital 
or acquired immunodeﬁ  ciencies (2,3).
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Table. Timeline of natural infection of veterinarian with Mycoplasma  lipofaciens (strain ML64) from infected poults* 
Day 
Finding 01 †2 3 4 567
Isolation – M. l.  M. l.  M. l.  M. l.  –––
PCR result‡  – ND ND ND ND + – –
Clinical signs  None None None Throat pain, slight rhinitis Slight rhinitis, nasal pain  None None None
*–, negative; M.l., Mycoplasma lipofaciens (identified by immunobinding assay); ND, not done; +, positive.  
†Hatching of infected poults and demonstration of aerosol transmission among poults. 
‡Detection of mycoplasma DNA per Lierz et al. (5).LETTERS
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Urinary Tract 
Infection Caused by 
Capnophilic 
Escherichia coli
To the Editor: Increased atmo-
spheric CO2 concentrations promote 
the growth of fastidious microorgan-
isms. However, the possibility that a 
strain of Escherichia coli can be CO2 
dependent is exceptional (1). 
An isolate of capnophilic E. coli 
was responsible for a urinary tract in-
fection (UTI) in a 77-year-old woman 
at the University Hospital of Guadala-
jara (Spain) in November 2002. Urine 
was cultured on a cystine-lactose-
electrolyte-deﬁ   cient agar plate and 
incubated at 37°C in an atmosphere 
containing 6% CO2 for 1 day. After 
24 hours, the culture yielded gram-
negative rods (>105 CFU/mL) in pure 
culture. The organism was motile, 
catalase positive, and oxidase nega-
tive. The strain could not be identiﬁ  ed 
by using the MicroScan WalkAway-40 
system (DadeBerhing, Inc., West Sac-
ramento, CA, USA). A subculture was 
performed, and the organism did not 
grow on sheep blood agar and Mac-
Conkey agar plates at 37°C in ambient 
air. However, a subculture incubated 
at 37°C for 24 hours in an atmosphere 
of 6% CO2 produced smooth colonies 
2–3 mm in diameter on sheep blood 
agar and MacConkey agar plates. 
The organism fermented lactose, and 
the indole reaction (BBL DrySlidet, 
Becton Dickinson Co., Sparks, MD, 
USA) performed on sheep blood agar 
was negative. The strain grew well on 
Schaedler agar plates after anaerobic 
incubation for 48 hours. The isolate 
remained capnophilic after 5 subcul-
tures. The strain was identiﬁ  ed as E. 
coli by using the Biolog GN2 panel 
(Biolog, Inc., Hayward, CA, USA) 
(100%, T = 0,534), after incubation 
of the panel in an atmosphere contain-
ing 6% CO2 for 1 day. The API 20E 
system (bioMérieux, Marcy-l’Etoile, 
France) according to the manufac-
turer’s instructions without C02 in-
cubation also identiﬁ  ed E. coli (pro-
ﬁ  le 5004512). The identiﬁ  cation was 
conﬁ   rmed by means of 16S rDNA 
sequence analysis (1,472 bp obtained 
by PCR ampliﬁ  cation by a previously 
reported method [2]), which showed 
99% similarity with E. coli sequence 
(GenBank accession no. CP000802). 
The 16S sequence showed similarity 
with  Shigella species; however, this 
identiﬁ  cation was not considered be-
cause the strain fermented lactose on 
MacConkey agar and agglutinations 
with  Shigella antiserum were nega-
tive. The original 16S rDNA sequence 
was deposited in GenBank (accession 
no. EU555536).
The antimicrobial drug sus-
ceptibility proﬁ  le  was  determined 
by incubating Mueller-Hinton agar 
plates at 37°C in an atmosphere con-
taining 6% CO2 by the disk diffu-
sion method, according to National 
Committee for Clinical Laboratory 
Standards recommendations (3). 
The isolate was susceptible to am-
picillin, amoxicillin/clavulanic acid, 
piperacillin, cefazolin, cefuroxime, 
cefotaxime, nitrofurantoin, fosfomy-
cin, trimethoprim-sulfamethoxazole, 
gentamicin, tobramycin, amikacin, 
norﬂ  oxacin, and ciproﬂ  oxacin. MICs 
were obtained for the following an-
timicrobial agents with the E-test 
method (AB Biodisk, Solna, Swe-
den), performed on Mueller-Hinton 
agar plates incubated in a 6% CO2 
atmosphere: ampicillin (1.5 μg/mL), 
amoxicillin (3 μg/mL), cefotaxime 
(0.064 μg/mL), imipenem (0.094 μg/
mL), piperacillin (2 μg/mL), and cip-
roﬂ  oxacin (0.008 μg/mL).
E. coli is the most common patho-
gen among patients with uncomplicat-
ed UTIs (4). Two cases of UTIs due 
to carbon dioxide–dependent strains 
of E. coli have been reported (1). The 
mechanisms for development of CO2 
dependence are unknown (5). CO2 can 
play a role in the growth of E. coli as 
a substrate for carboxylation reactions 
(6). Other members of the family En-
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